Halyard Health hired investment bank Deutsche Bank to launch a sales process for the unit, sources told Reuters Monday. The sources — who note sales talks do not guarantee a divestiture — said a deal could be worth more than $600 million, according to the report.
The surgical and infection prevention unit represents Halyard Health’s largest business in terms of revenue, posting about $1 billion in sales for 2016. However, the unit’s sales have decreased year-over-year, limiting the company’s growth, reports Reuters. The divestiture would allow Haylard Health to shift focus away from hospital products to its medical device unit, which saw a 15 percent sales growth in the most recent quarter.
Halyard Health and Deutsche Bank did not immediately respond to Reuters’ request for comment.
More articles on supply chain:
Drug costs fluctuate by more than 600% worldwide: 4 study findings
SCOTUS ruling brings biosimilars to market faster: 4 things to know
Cancer drugs may be just as effective — and cheaper — at lower doses, oncologists say
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
